Although the long-term patency of saphenous vein grafts is very much limited by accelerated graft atherosclerosis (1, 2) , these vessels remain the most commonly used conduits for bypass of occlusive disease in the coronary and distal peripheral circulations. It has been speculated that the seeding of artificial graft materials with genetically engineered endothelial cells might reduce their tendency for thrombosis when placed in these small and medium-sized vessels (3) . To While vein graft remodeling results in a reduction of the high distensibility of veins and decreases wall stress to normal arterial levels (4) , this process involves formation of a neointimal layer of smooth muscle cells (SMCs) that is highly susceptible to accelerated atherosclerosis (2, 5) . Up to 50% of vein bypass grafts fail within a period of 10 years as a result of this occlusive disease (1, 2, 5) , whereas high patency rates are maintained for periods exceeding 15 years when arterial vessels without significant neointimas are used as bypass grafts (6) . In
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this study, we postulated that a genetic engineering strategy could be developed to induce vein grafts to follow a different path of arterial adaptation by which mechanical stability could be achieved by means of medial hypertrophy, thereby mimicking arterial structure and decreasing the grafts' susceptibility to atherosclerosis.
Vein grafts respond to two major stimuli: (i) injury due to manipulation and ischemia at the time of surgery and (ii) increased intraluminal pressure and shear stress exerted on the venous wall by the arterial environment. Injury to the vessel wall promotes neointima formation in arteries as well as veins (7) (8) (9) , and exposure to increased pressure in the absence of vascular injury can induce vascular hypertrophy without neointima formation (10) . Since (15) (16) (17) .
The following sequences of phosphorothioate ODNs were used: antisense rat cdc2 (position -9 to +9) (5'-GTCTTC-CATAGTTACTCA-3'); four-base-pair-mismatch (underlined) antisense cdc2 (5'-GTCTICCGTCGTTAGTCA-3'); antisense rat PCNA (position +4 to +22) (5'-GATCAG-GCGTGCCTCAAA-3'); and four-base-pair-mismatch antisense PCNA (5'-GAITAGTCGTACCTAAAA-3'). Sense and reverse-antisense sequences were also used as controls. (Fig. 1 A and B) . Evans 6 times those of ungrafted veins at 6 and 10 weeks, with a neointima-to-media ratio of about 1.5:1 ( Fig. 2A) mated the overall thickness of control grafts that exhibited extensive neointimal hyperplasia. Minimal neointimal formation was seen on some microscopic sections of antisense-treated grafts, but the majority of sections examined remained entirely free of this cellular accumulation. The media of antisense-treated vessels consisted of SMCs organized in their normal circumferential architecture and was delimited by an internal elastic lamina, in contrast to the marked cellular disarray that characterized the neointima of untreated and control ODN-treated grafts (Fig. 1  C-) .
By the sixth week after grafting, untreated and control transfected vein grafts were found to have lumenal-radius-towall-thickness ratios, which are proportional to wall stress, that approximated the values measured in adjacent carotid arteries. The medial hypertrophy seen in antisense-transfected vein grafts by 6 weeks similarly succeeded in reducing this ratio to near arterial levels (Fig. 2B) . The high distensibility of ungrafted veins was also found to be shifted in both control and antisense-treated grafts, which displayed length-tension relationships closer to the carotid artery than to the jugular veins from which they were derived (Fig. 3) . Furthermore, biochemical evidence of vascular hypertrophy was reflected in the increase in protein-to-DNA ratio of antisense-ODN-treated grafts from 103 + 2 at 2 weeks to 229 + 39 at 6 weeks, compared with the ratios of 210 + 27 observed in carotid arteries and 86 + 9 and 89 + 8 in control-ODN-treated and untreated grafts at 6 weeks, respectively (n = 4).
Six weeks after surgery in hypercholesterolemic rabbits, large numbers of foam cells identified immunohistochemically as macrophages were found throughout the intima of untreated and control-ODN-transfected grafts and in subendothelial accumulations that corresponded to areas of macroscopic plaque (n = 5, Fig. 4 ). However, no plaque formation was observed in any of the antisense-treated grafts placed in cholesterol-fed animals (n = 5 (19, 20) . While the neointimal hyperplasia that occurs in all vein grafts helps to achieve mechanical stability in these otherwise thin-walled conduits, it is believed that this neointima serves as the substrate for the development of atherosclerotic disease. In fact, strikingly better long-term patency rates have been achieved when arterial graft conduits devoid of significant neointima are used in bypass surgery (6 (22) (23) (24) . Our "arterialized" grafts not only displayed a structural, biochemical, and mechanical similarity to native arteries but also proved resistant to this accelerated vein graft atherosclerosis.
Despite the elimination of significant neointimal hyperplasia and its predilection for atherosclerosis in antisense-ODNtransfected grafts, these vessels did retain the capacity for adaptation to the arterial environment. The reduction of wall stress to normal arterial levels is known to be an important aspect of neointima formation in vein grafts (4, 23) . We found that the medial hypertrophy of antisense-treated grafts also succeeded in reducing the ratio of lumenal radius to vessel thickness, which is proportional to wall stress, to a level comparable to that of the carotid arteries into which the grafts were placed. The (25) . The results of this study support the hypothesis that the development of accelerated graft atherosclerosis depends also on the substrate of neointimal hyperplasia. Taken together, these data suggest that graft atherosclerosis involves the sequence of endothelial dysfunction, intimal hyperplasia, macrophage invasion, and foam cell accumulation. It is recognized that SMCs involved in neointimal hyperplasia undergo a phenotypic change from a contractile to a secretory state (5) , and these "activated" neointimal SMCs may release interleukin 6 (26), platelet-derived growth factor (27) 
